Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives

Bibliography

• SCHIMMEL P, TAO J, HILL J: Arninoacyl tRNA synthetases as targets for new anti-infectives. FASEB J. (1998) 12.1599–1609.
   PubMed Web of Science ®Google Scholar
• ••Discussion of aminoacyl-tRNA synthetases as antibacterialdrug discovery targets.
   Google Scholar
• GALLANT P, FINN J, KEITH D, WENDLER P: The identification of quality antibacterial drug discovery targets: A case study with aminoacyl-tRNA synthetases. Emer. Ther. Targets (2000) 4:1–10.
   Google Scholar
• ••Overview of screening results with aminoacyl-tRNAsynthetases.
   Google Scholar
• WENDLER PA, SILVERMAN JA: Antibacterial drug discovery: Progress with current targets. CUIT. Opin. Anti-infect. Invest. Drugs (2000) 2:125–132.
   Google Scholar
• •Review of anti-infective targets that are currently being pursued.
   Google Scholar
• DOOLITTLE WF, BROWN JR: Tempo, mode, theprogenote and the universal root. Proc. Natl. Acad. Sci. USA (1994) 91:6721–6728.
   PubMed Web of Science ®Google Scholar
• NAGEL GM, DOOLITTLE RF: Phylogenetic analysis ofthe aminoacyl-tRNA synthetases. j Mol Evol. (1995) 40:487–498.
   PubMed Web of Science ®Google Scholar
• BROWN JR, DOOLITTLE WF: Root of the universal treeof life based on ancient aminoacyl-tRNA synthetase gene duplications. Proc. Natl. Acad. Sci. USA (1995) 92:2441–2445.
   PubMed Web of Science ®Google Scholar
• BAINES PJ, JACKSON D, MELLOWS G, SWAISLAND AJ, TASKER TCG: Mupirocin: its chemistry and metabo-lism. In: Mupirocin - A Novel Topical Antibiotic. Wilkinson DS, Price JD (Eds.), Royal Society of Medicine International Congress and Symposium Series (1984):13–22.
   Google Scholar
• TAO J, WENDLER P, CONNELLY G et al.: Drug target validation: lethal infection blocked by inducible peptide. Proc. Natl. Acad. Sci. USA (2000) 97:783–786.
   PubMed Web of Science ®Google Scholar
• •The first example of in vivo target validation by expression of a small peptide.
   Google Scholar
• NASS G, PORALLA K, ZAHNER H: Effect of the antibiotic Borrelidin on the regulation of threonine biosynthetic enzymes in E. con Biochem. Biophys. Res. Commun. (1969) 34:84–91.
   PubMed Web of Science ®Google Scholar
• PAETZ W, NASS G: Biochemical and immunological characterization of threonyl-tRNA synthetase of two borrelidin-resistant mutants of Escherichia coli K12. Eur.J. Biochem. (1973) 35:331–337.
   PubMedGoogle Scholar
• GERKEN SC, ARFIN SM: Chinese hamster ovary cells resistant to borrelidin overproduce threonyl-tRNA synthetase. j Biol. Chem. (1984) 259:9202–9206.
   PubMed Web of Science ®Google Scholar
• KOHNO T, KOHDA D, HARUKI M, YOKOYAMA S, MIYAZAWA T: Nonprotein amino acid furanomycin, unlike isoleucine in chemical structure, is charged to isoleucine tRNA by isoleucyl-tRNA synthetase andm incorporated into protein. J. Biol. Chem. (1990) 265:6931–6935.
   PubMed Web of Science ®Google Scholar
• KATAGIRI K, TORI K, KIMURA Y, YOSHIDA T, NAGASAKIT, MINATO H: A new antibiotic. Furanomycin, an isoleucine antagonist. J Med. Chem. (1967) 10:1149–1154.
   Web of Science ®Google Scholar
• OGILVIE A, WIEBAUER K, KERSTEN W: Stringent controlof ribonucleic acid synthesis in Bacillus subtilis treated with granaticin. Biochem. J (1975) 152:517–522.
   PubMed Web of Science ®Google Scholar
• OGILVIE A, WIEBAUER K, KERSTEN W: Inhibition ofleucyl-transfer ribonucleic acid synthetase in Bacillus subtilis by granaticin. Biochem. J. (1975) 152:511–515.
   PubMed Web of Science ®Google Scholar
• GIBSON-CLAY G, BYRN SR, HEINSTEIN P: The interac-tion of granaticin with nucleic acids and pyruvate decarboxylase. j Pharm. Sci. (1982) 71:467–468.
   PubMed Web of Science ®Google Scholar
• WEISER J, JANDA I, MIKULIK K, TAX J: Interaction ofgranaticin B with the transcription system of Bacillus subtilis. Folia Microbiol. (1977) 22:329–338.
   PubMed Web of Science ®Google Scholar
• WERNER RG, THORPE LF, REUTER W, NIERHAUS KH: Indolmycin inhibits prokaryotic tryptophanyl-tRNA ligase. Eur.J. Biochem. (1976) 68:1–3.
   PubMedGoogle Scholar
• WERNER RG: Uptake of indolmycin in Gram-positivebacteria. Antimicrob. Agents Chemother. (1980) 18:858–862.
   PubMed Web of Science ®Google Scholar
• KONRAD I, ROSCHENTHALER R: Inhibition ofphenylalanine tRNA synthetase from Bacillus subtilis by ochratoxin A. FEBS Lett. (1977) 83:341–347.
   PubMed Web of Science ®Google Scholar
• DIRHEIMER G, CREPPY EE: Mechanism of action ofochratoxin A. IARC Sci. Publ. (1991) 115:171–186.
   PubMedGoogle Scholar
• CREPPY EE, MAYER M, KERN D et al: In vitro inhibitionof yeast valyl-tRNA synthetase by the valine homologue of ochratoxin A. Biochim. Biophys. Acta (1981) 656:265–268.
   PubMed Web of Science ®Google Scholar
• CAPOBIANCO JO, ZAKULA D, COEN ML, GOLDMAN RC:Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action. Biochem. Biophys. Res. Commun. (1993) 190:1037–1044.
   PubMed Web of Science ®Google Scholar
• OKI T, HIRANO M, TOMATSU K, NUMATA K, KAMEI H:Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities. J. Antibiot. (Tokyo) (1989) 42:1756–1762.
   PubMed Web of Science ®Google Scholar
• ZIEGELBAUER K, BABCZINSKI P, SCHONFELD W: Molecular mode of action of the antifungal beta-amino acid BAY 10-8888. Antimicrob. Agents Chemother. (1998) 42:2197–2205.
   PubMed Web of Science ®Google Scholar
• ZIEGELBAUER K: Decreased accumulation or increasedisoleucyl-tRNA synthetase activity confers resistance to the cyclic beta-amino acid BAY 10-8888 in Candida albicans and Candida tropicalis. Antimicrob. Agents Chemother. (1998) 42:1581–1586.
   PubMed Web of Science ®Google Scholar
• KIRILLOV S, VITALI LA, GOLDSTEIN BP et al.: Purpuro-mycin: an antibiotic inhibiting tRNA aminoacylation. RNA (1997) 3:905–913.
   PubMed Web of Science ®Google Scholar
• TRANI A, KETTENRING J, RIPAMONTI F, GOLDSTEIN B, CIABATTI R: Chemical modifications of the antibiotic purpuromycin. Farmaco (1993) 48:637–651.
   PubMedGoogle Scholar
• TRANI A, DALLANOCE C, FERRARI P, GOLDSTEIN B, RIPAMONTI F, CIABATTI R: Synthesis and antimicrobial activities of 4 -purpuromycin derivatives. Farmaco (1996) 51:503–512.
   PubMedGoogle Scholar
• TRANI A, DALLANOCE C, PANZONE G, RIPAMONTI F, GOLDSTEIN BP, CIABATTI R: Semisynthetic derivatives of purpuromycin as potential topical agents for vaginal infections. J. Merl. Chem. (1997) 40:967–971.
   PubMed Web of Science ®Google Scholar
• FULLER AT MG, WOOLFORD M, BANKS GT, BARROW KD, CHAIN EB: Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature (1971) 234 :416–417.
   PubMed Web of Science ®Google Scholar
• HUGHES J, MELLOWS G: Interaction of pseudomonic acid A with Escherichia colt B isoleucyl-tRNA synthetase. Biochem. J. (1980) 191:209–219.
   PubMed Web of Science ®Google Scholar
• GILBART J, PERRY CR, SLOCOMBE B: High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob. Agents Chemother. (1993) 37:32–38.
   PubMed Web of Science ®Google Scholar
• FARMER TH, GILBART J, ELSON SW: Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. J. Antimicrob. Chemother. (1992) 30:587–596.
   PubMed Web of Science ®Google Scholar
• HODGSON JE, CURNOCK SP, DYKE KG, MORRIS R, SYLVESTER DR, GROSS MS: Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob. Agents Chemother. (1994) 38:1205–1208.
   PubMed Web of Science ®Google Scholar
• SCHIMMEL PR, SOLL D: Arninoacyl-tRNA synthetases: general features and recognition of transfer RNAs. Ann. Rev. Biochem. (1979) 48:601–648.
   PubMed Web of Science ®Google Scholar
• YU XY, HILL JM, YU G et al: Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNAsynthetases. Bioorg. Med. Chem. Lett. (1999) 9: 375–380.
   PubMed Web of Science ®Google Scholar
• HOUNTONDJI C, DESSEN P, BLANQUET S: Sequence similarities among the family of aminoacyl-tRNA synthetases. Biochimie (1986) 68:1071–1078.
   PubMed Web of Science ®Google Scholar
• WEBSTER T, TSAI H, KULA M, MACKIE GA, SCHIMMEL P:Specific sequence homology and three-dimensional structure of an aminoacyl transfer RNA synthetase. Science (1984) 226:1315–1317.
   PubMed Web of Science ®Google Scholar
• LUDMERER SW, SCHIMMEL P: Gene for yeast glutaminetRNA synthetase encodes a large amino-terminal extension and provides a strong confirmation of the signature sequence for a group of the aminoacyl-tRNA synthetases. J. Biol. Chem. (1987) 262:10801–10806.
   PubMed Web of Science ®Google Scholar
• CUSACK S, BERTHET-COLOMINAS C, HARTLEIN M, NASSAR N, LEBERMAN R: A second class of synthetase structure revealed by X-ray analysis of Escherichia colt seryl-tRNA synthetase at 2.5 A. Nature (1990) 347:249–255.
   Google Scholar
• ERIANI G, DELARUE M, POCH 0, GANGLOFF J, MORAS D: Partition of tRNAsynthetases into two classes based on mutually exclusive sets of sequence motifs. Nature (1990) 347:203–206.
   PubMed Web of Science ®Google Scholar
• BROWN MJ, MENSAH LM, DOYLE ML et al.: Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry (2000) 39:6003–6011.
   PubMed Web of Science ®Google Scholar
• POPE AJ, LAPOINTE J, MENSAH L, BENSON N, BROWN MJ, MOORE KJ: Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. I: Kinetic mechanism of the substrate activation reaction studied by transient and steady-state techniques. J. Biol. Chem. (1998) 48:31680–31690.
   Google Scholar
• •Kinetic characterisation of isoleucyl-tRNA synthetase during substrate activation.
   Google Scholar
• POPE AJ, MOORE KJ, MCVEY M et al: Characterization of isoleucyl-tRNA synth etase from Staphylococcus aureus. II: Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics. J. Biol. Chem. (1998) 48:31691–31701.
   Google Scholar
• •Comparison of the mechanisms of inhibition by various isoleucyl-tRNA synthetase inhibitors.
   Google Scholar